Analysis of Diagnostic Value of CTC and CTDNA in Early Lung Cancer.

This paper is the exploration and analysis of the diagnostic value of circulating tumor cells (CTC) and circulating tumor deoxyribonucleic acid (ctDNA) in early non-small cell lung cancer (NSCLC).A total of 125 NSCLC patients that hospitalized from March 2019 to December 2020 were selected, of which 64 subjects with stage I-II were listed as the early-stage group, and 61 patients with stage III-IV were classified as the intermediate-advanced group; In addition, 47 patients with benign pulmonary nodules hospitalized within same period were selected as a group of benign pulmonary nodules, and 50 healthy subjects were enrolled as a control group. The levels of CTC and ctDNA, serum tumor markers carcinoembryonic antigen (CEA), neuron-specific enolase (NSE), cytokeratin 21-1 (CYFRA21-1) and gastrin-releasing peptide precursor (pro-GRP) were detected. The diagnostic value of CTC and ctDNA in early NSCLC patients was analyzed by ROC curve. The area under the curve of CTC count for early-stage lung cancer was 0. 949 (P=0. 000, 95%CI: 0. 918-0. 980), and ctDNA was 0. 914 (P=0. 000, 95%CI: 0. 866~0. 963). There were significant differences in CTC count and ctDNA among subjects in each group (P<0. 05). CTC count and ctDNA of the early and intermediate-advanced group were remarkably higher than those of the control group and group of benign pulmonary nodules (P<0. 05), and CTC count and ctDNA of patients in the middle-late group were critically higher than those in the early-stage group (P<0. 05). There were significant differences in serum CEA, NSE, CYFRA21-1 and pro-GRP levels among all groups (P<0. 05). The results showed that CTC and ctDNA in NSCLC patients were significantly positively correlated with CEA, NSE, CYFRA21-1 and pro-GRP (P<0. 05).  Peripheral blood CTC and ctDNA levels are significantly increased in NSCLC patients. They are positively correlated with serum tumor markers CEA, NSE, CYFRA21-1 and pro-GRP levels, and are related to tumor progression. CTC and ctDNA have high value in the clinical diagnosis of early NSCLC.

[1]  R. Rintoul,et al.  Residual ctDNA after treatment predicts early relapse in patients with early-stage non-small cell lung cancer , 2022, Annals of oncology : official journal of the European Society for Medical Oncology.

[2]  A. Chaudhuri,et al.  Circulating Tumor DNA Minimal Residual Disease Detection of Non-Small-Cell Lung Cancer Treated With Curative Intent. , 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  Ji He,et al.  Perioperative ctDNA-based Molecular Residual Disease Detection for Non-Small Cell Lung Cancer: A Prospective Multicenter Cohort Study (LUNGCA-1). , 2021, Clinical cancer research : an official journal of the American Association for Cancer Research.

[4]  Toshihiro Ito,et al.  Vein-first Lobectomy for Lung Cancer Assessed According to the Status of Clustered Circulating Tumour Cells. , 2021, Cancer diagnosis & prognosis.

[5]  Adith S. Arun,et al.  Detection and characterization of lung cancer using cell-free DNA fragmentomes , 2021, Nature Communications.

[6]  Yang Shen,et al.  ICAM1 initiates CTC cluster formation and trans-endothelial migration in lung metastasis of breast cancer , 2021, Nature Communications.

[7]  N. Dashzeveg,et al.  EGFR inhibition blocks cancer stem cell clustering and lung metastasis of triple negative breast cancer , 2021, Theranostics.

[8]  G. Kallergi,et al.  Clinical Relevance of Mesenchymal- and Stem-Associated Phenotypes in Circulating Tumor Cells Isolated from Lung Cancer Patients , 2021, Cancers.

[9]  Yuhong Wang,et al.  FlowCell-enriched circulating tumor cells as a predictor of lung cancer metastasis , 2021, Human Cell.

[10]  V. Georgoulias,et al.  Assessment of the Efficacy and Clinical Utility of Different Circulating Tumor Cell (CTC) Detection Assays in Patients with Chemotherapy-Naïve Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) , 2021, International journal of molecular sciences.

[11]  K. Priya,et al.  Comparison assessment regarding the Awareness, Behaviors and Attitude towards HIV/AIDS of Dental students in comparison to other allied science , 2020, Science Progress and Research.

[12]  Harita Garg.  Digital Twin Technology: Revolutionary to improve personalized healthcare , 2020, Science Progress and Research.

[13]  Yutong He,et al.  Circulating Tumor Cell and Metabolites as Novel Biomarkers for Early-Stage Lung Cancer Diagnosis , 2020, Frontiers in Oncology.

[14]  R. López-López,et al.  Immunotherapy in nonsmall-cell lung cancer: current status and future prospects for liquid biopsy , 2020, Cancer Immunology, Immunotherapy.

[15]  You Lu,et al.  Pseudoprogression and hyperprogression in lung cancer: a comprehensive review of literature , 2020, Journal of Cancer Research and Clinical Oncology.

[16]  Q. Liu,et al.  Construction of CTC-ALK gene fusion detection system based on the multi-site magnetic separation in lung cancer and its clinical verification. , 2020, Neoplasma.

[17]  C. Marquette,et al.  Circulating tumour cells as a potential biomarker for lung cancer screening: a prospective cohort study. , 2020, The Lancet. Respiratory medicine.

[18]  P. Robson,et al.  Single-cell analyses reveal increased intratumoral heterogeneity after the onset of therapy resistance in small-cell lung cancer , 2020, Nature Cancer.

[19]  Nallasivam Palanisamy,et al.  High-Throughput Label-Free Isolation of Heterogeneous Circulating Tumor Cells and CTC Clusters from Non-Small-Cell Lung Cancer Patients , 2020, Cancers.

[20]  D. Planchard,et al.  Acquired Resistance Mutations to ALK Inhibitors Identified by Single Circulating Tumor Cell Sequencing in ALK-Rearranged Non–Small-Cell Lung Cancer , 2019, Clinical Cancer Research.

[21]  Jun Wang,et al.  Perioperative Dynamic Changes in Circulating Tumor DNA in Patients with Lung Cancer (DYNAMIC) , 2019, Clinical Cancer Research.

[22]  M. Lawrence,et al.  Combination Olaparib and Temozolomide in Relapsed Small Cell Lung Cancer. , 2019, Cancer discovery.

[23]  Q. Tan,et al.  Effect of Vein-First vs Artery-First Surgical Technique on Circulating Tumor Cells and Survival in Patients With Non-Small Cell Lung Cancer: A Randomized Clinical Trial and Registry-Based Propensity Score Matching Analysis. , 2019, JAMA surgery.

[24]  B. Tong,et al.  Circulating tumor cells in patients with lung cancer: developments and applications for precision medicine. , 2019, Future oncology.

[25]  X. Xie,et al.  Inferring the Evolution and Progression of Small-Cell Lung Cancer by Single-Cell Sequencing of Circulating Tumor Cells , 2019, Clinical Cancer Research.

[26]  W. Liang,et al.  Non-invasive diagnosis of early-stage lung cancer using high-throughput targeted DNA methylation sequencing of circulating tumor DNA (ctDNA) , 2019, Theranostics.

[27]  Shuyi Wang,et al.  Crosstalk between cancer cells and tumor associated macrophages is required for mesenchymal circulating tumor cell-mediated colorectal cancer metastasis , 2019, Molecular Cancer.

[28]  Y. Chae,et al.  Detection of Minimal Residual Disease Using ctDNA in Lung Cancer: Current Evidence and Future Directions. , 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[29]  A. Gupta,et al.  Early Reduction in ctDNA Predicts Survival in Patients with Lung and Bladder Cancer Treated with Durvalumab , 2018, Clinical Cancer Research.

[30]  Ash A. Alizadeh,et al.  Early Detection of Molecular Residual Disease in Localized Lung Cancer by Circulating Tumor DNA Profiling. , 2017, Cancer Discovery.

[31]  Geno Saccomanno,et al.  Early diagnosis of lung cancer , 1991, Photonics West - Lasers and Applications in Science and Engineering.